The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Should all elderly patients with AML receive azacitidine as post-remission therapy?
Featured:
Esther Natalie OlivaDuring the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Esther Natalie Oliva, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, IT. We asked: Should all elderly patients with acute myeloid leukemia receive azacitidine as post-remission therapy?
Esther Natalie Oliva explains that based on the results of the trial comparing subcutaneous azacitidine with best supportive care, there is no clear evidence of benefits in all patients. However, in elderly patients (above 69 years) receiving azacitidine disease-free survival was significantly prolonged. Another trial comparing the oral formulation of azacitidine vs placebo showed benefits for patients receiving azacitidine as post-remission therapy.
Should all elderly patients with AML receive azacitidine as post-remission therapy?
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?